STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, today announced it has ...
Biosynex SA (FR:ALBIO) has released an update. Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test ...
A manufacturer of rapid diagnostic tests in Hauppauge has paid $500,000 to end an investigation by the U.S. Securities and Exchange Commission, according to a securities filing. Chembio Diagnostics ...
STRASBOURG, France and HAUPPAUGE, N.Y., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA: ALBIO), a French market leader specializing in the design and distribution of rapid tests, and ...
Dublin, June 23, 2020 (GLOBE NEWSWIRE) -- The "HIV Self-test Kits - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering. The Global HIV Self-test Kits market ...
BIOSYNEX SA BIOSYNEX SA: CHEMBIO DIAGNOSTICS INC., A SUBSIDIARY OF BIOSYNEX, RECEIVES A GRANT FOR DEVELOPMENT OF A DPP CONGENITAL SYPHILIS ASSAY 23-Oct-2024 / 18:00 CET/CEST Dissemination of a French ...
A financially strapped Hauppauge-based manufacturer of diagnostic tests is being purchased by a French test maker for $17.2 million in cash, officials said. Chembio Diagnostics Inc. has signed a ...
Chembio Diagnostics, Inc. (CEMI) becomes the first North American structure controlled by Biosynex in North America STRASBOURG, France, April 27, 2023 (GLOBE NEWSWIRE) -- Biosynex SA (“Biosynex”) (EPA ...
Complementary Technologies, Product Portfolios, and Market Opportunities Expected to Represent Significant Growth Drivers Consolidated Manufacturing, Sales, Marketing, Operations to Provide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback